Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M

ROCKWELL MEDICAL, INC.

Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.
Q4 2025 gross margin 21% (up from 15% Q4 2024), a company record; full-year gross margin 17% in line with guidance.
Full-year 2025 net loss $5.3M (vs $0.5M loss in 2024) including $4.0M non-cash charges and $1.2M severance/facility costs.
Adjusted EBITDA Q4 2025 $1.0M; full-year $0.3M, second consecutive profitable year on that basis; cash grew to $25.0M.
2026 guidance: Adjusted EBITDA $1M–$2M, positive operating cash flow; pricing increase under extended purchase agreement through Dec 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2025 results: revenue $18.3 million, net income $ (0.6) million, EPS $ (0.01) per share.

Period: the three months ended December 31, 2025
Revenue: $18.3 million
Net income: $ (0.6) million
EPS: $ (0.01) per share
Result: reported results

Exact text from the filing

EX-99.1 (EX-99.1) --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2025 results: revenue $69.3 million, net income $ (5.3) million, EPS $ (0.15) per share.

Period: the twelve months ended December 31, 2025
Revenue: $69.3 million
Net income: $ (5.3) million
EPS: $ (0.15) per share
Result: reported results

Exact text from the filing

--- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth quarter 2025,

View on SEC.gov

Browse all earnings releases →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-021176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.